Paul Tudor Jones Merus N.V. Transaction History

Tudor Investment Corp Et Al

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$39.81 - $60.2 $410,560 - $620,842	10,313 Added 32.18%	42,359 $2.51 Million
Q1 2024 May 15, 2024	BUY	$28.03 - $51.82 $213,112 - $393,987	7,603 Added 31.11%	32,046 $1.44 Million
Q4 2023 Feb 14, 2024	BUY	$20.06 - $28.66 $16,148 - $23,071	805 Added 3.41%	24,443 $672,000
Q3 2023 Nov 15, 2023	BUY	$20.13 - $27.29 $14,413 - $19,539	716 Added 3.12%	23,638 $557,000
Q2 2023 Aug 14, 2023	BUY	$18.33 - $27.18 $97,277 - $144,244	5,307 Added 30.13%	22,922 $603,000
Q1 2023 May 15, 2023	SELL	$14.25 - $20.5 $79,800 - $114,800	-5,600 Reduced 24.12%	17,615 $324,000
Q4 2022 Feb 14, 2023	BUY	$12.8 - $23.66 $2,176 - $4,022	170 Added 0.74%	23,215 $359,000
Q3 2022 Nov 14, 2022	BUY	$18.64 - $28.93 $23,859 - $37,030	1,280 Added 5.88%	23,045 $462,000
Q2 2022 Aug 15, 2022	BUY	$13.98 - $29.25 $104,794 - $219,258	7,496 Added 52.53%	21,765 $493,000
Q1 2022 May 16, 2022	SELL	$23.58 - $30.91 $100,922 - $132,294	-4,280 Reduced 23.07%	14,269 $377,000
Q4 2021 Feb 14, 2022	BUY	$20.0 - $32.29 $370,980 - $598,947	18,549 New	18,549 $590,000

200

62M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $1.88B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.